PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 509.90 thousand shares for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2017-09-28
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2017 was 509.90K shares.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2015 was 84.24K shares, a 328.31% increase from fiscal 2014.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2014 was 19.67K shares, a 47.60% decline from fiscal 2013.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2013 was 37.53K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|
| 2017-06-30 | 509.90K shares 10-K · filed 2017-09-28 |
| 2015-06-30 | 84.24K shares 10-K · filed 2017-09-28 |
| 2014-06-30 | 19.67K shares 10-K · filed 2016-09-09 |
| 2013-06-30 | 37.53K shares 10-K · filed 2015-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |